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Background: The original aim of the African Programme for Onchocerciasis Control (APOC) was to control
onchocerciasis as a public health problem in 20 African countries. In order to identify all high risk areas where
ivermectin treatment was needed to achieve control, APOC used Rapid Epidemiological Mapping of Onchocerciasis
(REMO). REMO involved spatial sampling of villages to be surveyed, and examination of 30 to 50 adults per village
for palpable onchocercal nodules. REMO has now been virtually completed and we report the results in two
articles. A companion article reports the delineation of high risk areas based on expert analysis. The present article
reports the results of a geostatistical analysis of the REMO data to map endemicity levels and estimate the number
infected.
Methods: A model-based geostatistical analysis of the REMO data was undertaken to generate high-resolution
maps of the predicted prevalence of nodules and of the probability that the true nodule prevalence exceeds the
high risk threshold of 20%. The number infected was estimated by converting nodule prevalence to microfilaria
prevalence, and multiplying the predicted prevalence for each location with local data on population density. The
geostatistical analysis included the nodule palpation data for 14,473 surveyed villages.
Results: The generated map of onchocerciasis endemicity levels, as reflected in the prevalence of nodules, is a
significant advance with many new endemic areas identified. The prevalence of nodules was > 20% over an area of
2.5 million km2 with an estimated population of 62 million people. The results were consistent with the delineation
of high risk areas of the expert analysis except for borderline areas where the prevalence fluctuated around 20%. It
is estimated that 36 million people would have been infected in the APOC countries by 2011 if there had been no
ivermectin treatment.
Conclusions: The map of onchocerciasis endemicity levels has proven very valuable for onchocerciasis control in
the APOC countries. Following the recent shift to onchocerciasis elimination, the map continues to play an
important role in planning treatment, evaluating impact and predicting treatment end dates in relation to local
endemicity levels.
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Onchocerciasis, or river blindness, used to be endemic
in some 30 countries in Africa where over 99% of all
cases in the world were found [1]. The Onchocerciasis
Control Programme in West Africa (OCP) has success-
fully controlled onchocerciasis by large scale vector con-
trol in the savanna belt of nine West African countries
[2]. In the remaining endemic African countries, where
some 85% of onchocerciasis cases lived, onchocerciasis
control became feasible with the registration of ivermec-
tin for the treatment of human onchocerciasis in 1987
and its donation free of charge for as long as needed
[3,4]. Clinical and community trials demonstrated that
annual ivermectin treatment could effectively control the
disease [5], and Non-Governmental Development Organi-
zations initiated the first ivermectin distribution efforts
[6]. In 1995 the African Programme for Onchocerciasis
Control (APOC) was created to support the establishment
of community directed treatment with ivermectin (CDTI)
in all remaining areas in Africa where onchocerciasis was
a public health problem [7].
One of the first challenges for APOC was to determine
where exactly onchocerciasis was a public health prob-
lem. The existing information on the geographic distri-
bution of onchocerciasis in the 20 APOC countries
[1,8-32] was incomplete and not reliable enough for tar-
geting ivermectin treatment programmes, and there was
an urgent need for comprehensive mapping of the geo-
graphic distribution of onchocerciasis in all potentially
endemic countries in Africa outside the OCP [7,33]. This
was a vast area of some 14 million km2 and the survey
methods available were difficult to implement at such a
large scale. In anticipation of this problem, the WHO
Special Programme for Research and Training in Tropical
Diseases (TDR) developed a rapid assessment method in
1993, Rapid Epidemiological Mapping of Onchocerciasis
(REMO) [34]. In REMO, sample villages are selected using
a sampling methodology that takes the spatial epidemi-
ology of onchocerciasis into account. Rapid assessment
surveys are then carried out in the selected villages to esti-
mate the prevalence of palpable onchocercal nodules as a
proxy for the prevalence of onchocerciasis infection. Fol-
lowing its successful field testing in Cameroon and Nigeria
[35], APOC adopted REMO for large-scale mapping of
onchocerciasis in all APOC countries in order to identify
priority areas for CDTI. Large scale application of REMO
started in 1996, and has since been applied in phase with
the expansion of CDTI to cover all potentially endemic
areas in APOC countries [33].
To date, virtually all potentially endemic areas in the 20
APOC countries have been mapped for onchocerciasis
through REMO. In a companion paper we summarize the
REMO surveys and show the results of an expert analysis
that was undertaken to delineate high-risk areas whereonchocerciasis was a major public health problem and
where ivermectin treatment was a priority [36]. Based on
these maps of high risk areas, CDTI projects were created
that by 2012 were treating over 80 million people in the
APOC countries [37].
In the present article we report the results of a more ad-
vanced analysis of the REMO data using a model-based
geostatistical methodology that has allowed a more effect-
ive utilization of the extensive REMO data. One important
application was the mapping of the geographic distribu-
tion of onchocerciasis endemicity levels as reflected in the
prevalence of palpable onchocercal nodules. Endemicity is
a key concept in onchocerciasis epidemiology. The sever-
ity of the disease and the public health importance of on-
chocerciasis in a given area are directly related to the local
level of endemicity [38,39]. The endemicity level is also an
important indicator of the local potential for transmission,
as well as a predictor of the intensity and duration of in-
terventions needed to control or eliminate onchocerciasis
in an onchocerciasis focus [40]. It is therefore important
for onchocerciasis control programmes to have a detailed
map of onchocerciasis endemicity levels throughout their
operational area.
In 1979, Prost et al. [41] defined three levels of oncho-
cerciasis endemicity in terms of the community prevalence
of Onchocerca volvulus microfilaria in the skin: hyperen-
demic onchocerciasis (prevalence of microfilaria > 60%),
where the disease is very severe and associated with onch-
ocercal blindness rates in excess of 4 to 5% in the West
African savanna; hypoendemic onchocerciasis (preva-
lence of microfilaria <35%) where ocular complications
are rare and the disease is socially not apparent, and
mesoendemic onchocerciasis (prevalence of microfilaria
between 35% and 60%) where the disease pattern varied
between these two extremes. The prevalence of nodules
is related to the prevalence of skin microfilaria. Using
the quantification of this relationship by Coffeng et al.
[42], the above endemicity classes translate into hyperen-
demic onchocerciasis for a prevalence of palpable nodules
in adults > 45%, mesoendemic onchocerciasis for a nodule
prevalence between 20% and 45%, and hypoendemicity for
a prevalence of nodules < 20%.
When ivermectin became available for onchocerciasis
control, a WHO expert meeting recommended that in
order to control onchocerciasis as a public health prob-
lem, ivermectin treatment was urgent in communities
with a prevalence of nodules in adult males > 40% and
highly desirable for a nodule prevalence > 20%, i.e. in all
meso and hyper endemic communities [43]. Based on
this recommendation, APOC’s aim was to establish CDTI
in all high risk areas where the prevalence of palpable nod-
ules in adults was greater than 20% [33]. A first application
of the geostatistical analysis was to delineate all areas
where the estimated prevalence was > 20% and to compare
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the expert analysis as reported in the companion paper.
We also used the geostatistical analysis to provide popula-
tion estimates by endemicity level, and to predict how
many people would have been infected with O. volvulus in
the APOC countries if there had been no onchocerciasis
control.Methods
REMO methodology
The geographic distribution of onchocerciasis is deter-
mined by the availability of breeding sites for the Simulium
vectors in fast flowing rivers and streams, and the limited
flight range of the vector when seeking a blood meal. The
spatial epidemiology of onchocerciasis is therefore closely
related to the distribution and suitability of local river
systems. REMO is based on this knowledge and consists
of three stages [34]:
1) The division of the area to be mapped into
biogeographic zones that are reasonably uniform
with regard to their potential for onchocerciasis and
that cover the watersheds of the main local drainage
systems. Areas that are known to be unsuitable for
the vector for ecological reasons (absence of fast
flowing water, high altitude, etc.) and uninhabited
areas (e.g. national parks) are excluded at this stage.
2) The selection of a sample of villages to be surveyed
in order to determine whether onchocerciasis is
present or not and, if present, to give a rough
indication of the distribution and severity of
onchocerciasis in the zone. This sampling uses the
available information on the local river system
3) Rapid epidemiological assessment (REA) surveys in
the selected villages. A sample of 30 to 50 adult
males who have resided in the village for more than
10 years are examined for the presence of nodules,
and the percentage of males with palpable nodules is
calculated. The geographic coordinates of each
village are collected by applying a Global Positioning
System (GPS) in a central location in the village.
More details of the REMO methodology are provided
in the companion paper [36] and the WHO Manual for
Rapid Epidemiological Mapping of Onchocerciasis [34].
The companion paper also describes the implementation
of REMO in APOC countries and ethical considerations
in undertaking the REMO surveys.Analysis of REMO data
The analysis of the REMO data was undertaken using
two analytical approaches: an expert analysis using the
original REMO analytical methodology for which theresults are reported in the companion article [36], and a
geostatistical analysis which is described here.Geographic information system (GIS)
All relevant geographic information was processed using
ArcGIS 10 (ESRI Inc., Redlands, USA).
The geographic information used for the analysis
included:
– National and administrative boundaries, rivers and
lakes, national parks, main roads, villages and urban
settlements (source WHO HealthMapper http://
health-mapper-release-5.software.informer.com).
– Topography and relief (source ESRI http://services.
arcgisonline.com/ArcGIS/rest/services/World_Shaded_
Relief/MapServer)
– Population density at 30 arc seconds resolution (source
LandScan http://www.ornl.gov/sci/landscan/index.
shtml)
– Total surface area per country, including water bodies.
http://wdi.worldbank.org/table/1.1
– Areas that are unsuitable for onchocerciasis as
defined during the first REMO phase (see above)
– Geographic coordinates of all surveyed villages and
for each surveyed village the percentage of examined
adults who had palpable nodules, referred to as the
“prevalence of nodules” or nodule prevalence.
– Surveyed area. This is the total area within 50 km
from the nearest surveyed village. The threshold of
50 km corresponds to the maximum acceptable
distance between sample villages as defined in the
REMO manual [34]. Areas beyond 50 km from the
nearest surveyed village are classified as non-surveyed.
Excluded from both the surveyed and non-surveyed
areas are unsuitable areas, national parks and water
bodies.Geostatistical analysis
For probabilistic prediction of the true prevalence at
both sampled and unsampled locations, a geostatistical
model [44] was fitted in which conditional on the true
prevalence P(x) at location x, the number of positives, Y,
amongst a sample of N individuals follows a binomial
distribution with N trials and “success” probability P(x).
We used a standard logistic link function log(P(x)/(1 − P
(x))) = μ + S(x), where S(x) is a low-rank approximation
to a zero-mean isotropic Gaussian process [45]. For the
main analysis, which excluded the spatially separate
areas of Liberia and the island of Bioko, this process is
defined as follows: (1) choose a discrete set of M points,
say Xj, over the region of interest; (2) represent S(x) as a
weighted average of M independent, identically distrib-
uted zero-mean Gaussian variables Zj with variance σ
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Zj , where the weights w(Xj − x) are
chosen as functions of the great-circle distance, say uj,
between x and each of the Xj, so as to approximate the
required correlation function of S(x). Note that, in this
case, the variance σ2 does not represent variability on
the logit scale since the range of variation of the Zj var-
iables is scaled by the kernel weights w(Xj − x). Follow-
ing the procedure suggested by Rodriguez and Diggle
[46], we used M = 10734 points Xj in a regular lattice at
spacing 0.1 by 0.1 degrees and weights w Xj−x







=φ to approximate a Matérn correlation
function ([44] p.51-52) with scale parameter φ and
smoothness parameter κ = 2.
In the separate analyses for Liberia and Bioko the
dimensionality was much lower and there was no need
of a low rank approximation of S(x). In these analyses, the
zero-mean isotropic Gaussian process S(x) has Matérn
correlation function, as previously defined, and vari-
ance τ2, which represents, unlike σ2, variation on the
logit scale.
In each of the three analyses, model parameters were
then estimated using the method of maximum likeli-
hood based on the Laplace approximation method [47].
Maximum likelihood estimates, with associated 95% confi-
dence intervals, of the geostatistical model parameters were
for the main analysis (all REMO data excluding Liberia and
Bioko) μ^ ¼ −2:451 (−2.469, −2.432), σ^ 2 ¼ 31:570 (31.038,
32.112) and φ^ ¼ 65:208 (64.993, 66.301) km. For Liberia
the parameter estimates were μ^ ¼ −1:759 (−1.779, −1.739),
τ^2 ¼ 0:486 (0.432, 0.547) and φ^ ¼ 57:945 (52.151, 64.381)
km. Finally for Bioko the estimates were μ^ ¼ −0:079
(−0.283, 0.125), τ^2 ¼ 0:133 (0.057, 0.310) and φ^ ¼ 1:950
(0.535, 7.112) km. From the estimates of the scale pa-
rameters ϕ we determined that the range of the spatial
correlation, defined as the distance at which the spatial
correlation is 0.05 [44], is about 350 km for the main
area, 311 km for Liberia and 10 km for Bioko. Hence
pairs of observations within these distances in each of the
three areas will show non-negligible spatial correlation.
The output from the fitted geostatistical model is a
sample, of whatever desired size, from the joint predict-
ive distribution of P(x), i.e. the conditional distribution
of P(x) given all of the data, at locations x forming a
regular grid at spacing 1 km over the entire surveyed
area. A Monte Carlo Markov Chain method for condi-
tional simulation of P(x) is used, based on the approach
proposed by Giorgi et al. [48]. Any desired summaries of
the predictive distributions can then be calculated and
mapped. The two most relevant summaries for the
current population are the mean of the predictive distri-
bution of P(x) and the probability that P(x) exceeds 0.2(20%), which corresponds to the operational criterion for
delineating high-risk areas.
In order to deal with the high number of zero reported
disease cases, we added zero prevalence data-points in
areas free from the disease (ocean, deserts) when simu-
lating from the predictive distribution of P(x). The
fraction of added zeros corresponds to 5% of the total
sample size beyond which very little impact was ob-
served on the predicted prevalence surface. This ap-
proach decreases prevalence estimates in proximity of
boundaries with areas free from the disease and avoids
unrealistic high estimates of prevalence in such bound-
ary areas. All computations were run on the High End
Computer Cluster at Lancaster University, using the R
statistical software environment [49].
Estimation of population by endemicity level and number
infected
The ‘at risk population’ of the surveyed areas in each
APOC country was estimated by multiplying the surface
of the surveyed area in the country with the country-
specific average population density for CDTI projects.
The latter was obtained for each APOC country by divid-
ing the total population of the CDTI projects in the coun-
try in 2011 by the total surface area of these projects.
The nodule prevalence map was used to divide the sur-
veyed area in each country into three endemicity classes
with nodule prevalence of 0–4.5%, 5–19.9% and >20%
respectively. The population in each class was estimated
by multiplying the surface area with the average popula-
tion density for CDTI projects in the country. For all
surface calculations, the geographic coordinates were first
projected using the ARCGIS (World) Cylindrical Equal
Area projection.
In order to estimate the number of persons that would
have been infected with O. volvulus by the year 2011 if
there had been no onchocerciasis control, we used the
recently published results of a study on the relationship
between the prevalence of skin microfilaria in a village
(all age groups combined) and the prevalence of palpable
nodules in adult males in the same villages [42]. From
this publication we used the main relationship for all
study areas except one (Mbam), for which the pattern
was different. This relationship was used to convert the
1 km resolution predicted nodule prevalence in adults,
as generated during the geostatistical analysis, into the
corresponding predicted prevalence of microfilaria for all
ages combined. For each country, the predicted prevalence
of microfilaria was then averaged over the total surveyed
area and multiplied with the estimated at risk population
of the surveyed areas in the country to obtain an estimate
of the total number, T, infected with O. volvulus if there
had been no onchocerciasis control. To obtain a confi-
dence interval for this estimate, we sampled repeatedly
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P(x), and from each sample calculated the corresponding
estimate of T. Then, a 95% confidence interval for T is the
range from the 2.5th to the 97.5th percentile of the empir-
ical distribution of these estimates. For the APOC-wide
total we used a similar procedure. Since nodule prevalence
was modelled using three independent spatial processes
with different means for the main area, Liberia and Bioko,
we obtained a simulated sample for each from the joint
predictive distribution of P(x), the estimated number of in-
fected for the three areas separately and added these up.
The 95% confidence intervals were then calculated from
the resulting APOC-wide total distribution of T.
Results
Surveyed and excluded areas
The first step in the implementation of REMO was the
exclusion of areas that were considered unsuitable for
onchocerciasis transmission, and where, therefore, no
nodule surveys were carried out. Also excluded at this
stage were large water bodies and national parks that
were considered uninhabited. The extent of the excluded
areas in the different countries is summarised in Table 1.
Large excluded areas covering more than 50% of the






Angola 1,247 84 6.7
Burundi 28 4 13.0
Cameroon 475 25 5.2
CAR 623 129 20.6
Chad 1, 284 1, 027 80.0
Congo 342 59 17.1
DRC 2,345 183 7.8
Eq Guinea 28 4 15.2
Ethiopia 1,104 583 52.8
Gabon 268 19 7.3
Kenya 584 505 86.3
Liberia 96 1 0.8
Malawi 118 39 33.3
Mozambique 799 60 7.5
Nigeria 924 42 4.6
Rwanda 25 5 21.3
South Sudan 644 68 10.6
Sudan 1,861 1,516 81.4
Tanzania 947 380 40.1
Uganda 242 62 25.5
Total 13,986 4, 793 34.3and Sudan. A description of the main unsuitable areas is
provided in the companion paper [36].
The remaining areas after the above exclusions were
considered potentially endemic areas that needed to be
surveyed for onchocerciasis. Table 1 shows for each coun-
try the extent of the areas that were surveyed and of the
remaining non-surveyed area. In 8 countries all of the po-
tentially endemic areas were surveyed. In 6 other coun-
tries, all (Central African Republic and Gabon) or nearly
all (Angola, Cameroon, Congo and South Sudan) of the
non-surveyed areas were uninhabited or had a very low
population density of less than 1 person per km2. In only
2 of the remaining countries was the non-surveyed area
more than 10% of the country surface: Mozambique (17%)
and Tanzania (16%).
REMO surveys were carried out in a total of 14,473
sample villages in the surveyed areas in the 20 APOC
countries. Figure 1 provides a map showing the location
and observed prevalence in the sample villages and the
extent of the surveyed area.
Map of the estimated prevalence of palpable nodules
The model-based geostatistical analysis generated a map
of the predicted prevalence of palpable nodules at 1 km
resolution throughout the surveyed area in the 20C countries
Surveyed area Non-surveyed area
1000 km2 % 1000 km2 %
1,015 81.4 148 11.9
24 87.0 0 0.0
430 90.5 21 4.3
448 71.9 46 7.4
257 20.0 0 0.0
271 79.3 12 3.5
2,053 87.6 109 4.6
23 80.4 0 0.0
446 40.4 75 6.8
191 71.5 57 21.2
57 9.8 23 3.9
96 99.2 0 0.0
77 64.9 2 1.9
549 68.7 190 23.8
858 92.9 0 0.0
20 78.0 0 0.0
535 83.0 41 6.4
346 18.6 0 0.0
393 41.5 174 18.4
180 74.4 0 0.0
8,270 59.1 898 6.4
Figure 1 Map of the observed prevalence of palpable nodules in the 14,473 surveyed villages.
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timate of the geographic distribution of onchocerciasis
endemicity levels based on the model based analysis of
the REMO data. It shows substantial spatial variation
in onchocerciasis endemicity levels. There are some
vast areas where the endemicity levels are very high
with the estimated prevalence of nodules exceeding
40%. A vast belt of hyperendemic onchocerciasis ex-
tends from the Democratic Republic of Congo through
the west of South Sudan and the Central African Republic
to Cameroon and south east Nigeria. There are alsolarge hyperendemic foci in south Tanzania and west
Ethiopia. On the other end of the endemicity scale there
are several large areas where the prevalence of nodules
is close to 0. This includes an area of some 500,000 km2
in North and Central Congo, South West of the Central
African Republic and border areas of Cameroon, Gabon
and the Democratic Republic of Congo where the re-
sults suggest that onchocerciasis is not endemic. Similar
results were obtained for most of Mozambique, Malawi
and Uganda, and large sections of Tanzania, Ethiopia,
Sudan and Chad.
Figure 2 Map of the estimated prevalence of palpable nodules in the 20 APOC countries.
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Table 2 shows for each APOC country the classification
of the surveyed areas into three endemicity classes with
nodule prevalences of 0–4.9%, 5–19.9% and > 20% re-
spectively. The table also gives the estimated population
for these three categories for the year 2011. Overall, the
predicted prevalence of nodules is greater than 20% over
an area of 2.5 million km2 where an estimated 62 million
people live. Another 77 million people are estimated to
live in an area of 2.8 million km2 where the predicted
nodule prevalence is between 5% and 20%. There are four
countries, namely Cameroon, Central African Republic,
Democratic Republic of Congo and Liberia, where morethan 50% of the surveyed population live in areas where
the predicted nodule prevalence is greater than 20%. In
absolute numbers, the main countries are the Democratic
Republic of Congo with 23.3 million people living in areas
with more than 20% prevalence, Nigeria (14.3 million),
Ethiopia (5.9 million), and Cameroon (5.2 million).
Priority areas for large scale treatment
The main objective of the REMO surveys was to identify
priority areas for large-scale ivermectin treatment, i.e.
areas where the prevalence of nodules is greater than 20%.
The geostatistical analysis provides an objective method
for defining such areas while taking the statistical
Table 2 Surveyed area and population by estimated nodule prevalence in the 20 APOC countries
Country
Total surveyed area Surface (1000 km2) Estimated population (1000)
Estimated population as % of total


































Angola 3.8 1,015 3,812 278 570 166 1,046 2,142 625 27.4 56.2 16.4
Burundi 341.0 24 8,252 11 11 2 3,821 3,760 671 46.3 45.6 8.1
Cameroon 24.2 430 10,389 64 149 217 1,555 3,599 5,234 15.0 34.6 50.4
CAR 5.2 448 2,312 135 81 232 697 418 1,198 30.1 18.1 51.8
Chad 21.6 257 5,557 152 51 54 3,286 1,099 1,171 59.1 19.8 21.1
Congo 34.8 271 9,432 194 62 15 6,750 2,159 523 71.6 22.9 5.5
DRC 22.1 2,053 45,391 318 683 1,052 7,040 15,089 23,262 15.5 33.2 51.2
Eq Guinea 22.0 23 433 3 18 1 54 298 81 12.4 68.8 18.7
Ethiopia 46.7 446 20,842 168 152 126 7,844 7,094 5,904 37.6 34.0 28.3
Gabon NA 191 722 88 101 2 333 381 8 46.1 52.8 1.2
Kenya NA 57 3,035 57 0 0 3,035 0 0 100.0 0.0 0.0
Liberia 30.2 96 2,884 0 42 53 10 1,269 1,604 0.3 44.0 55.6
Malawi 237.4 77 18,245 61 11 4 14,529 2,708 1,008 79.6 14.8 5.5
Mozambique NA 549 9,889 483 65 1 8,694 1,170 25 87.9 11.8 0.2
Nigeria 65.3 858 56,016 175 463 220 11,440 30,239 14,336 20.4 54.0 25.6
Rwanda NA 20 9,550 19 1 0 9,550 0 0 100.0 0.0 0.0
South Sudan 13.8 535 7,380 115 206 214 1,591 2,842 2,947 21.6 38.5 39.9
Sudan 14.6 346 5,053 331 13 2 4,841 190 23 95.8 3.8 0.4
Tanzania 19.4 393 7,631 221 66 106 4,289 1,276 2,065 56.2 16.7 27.1
Uganda 56.4 180 10,135 128 28 24 7,208 1,556 1,371 71.1 15.4 13.5
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vides a map of the predicted probability that the local
prevalence of palpable nodules exceeds the threshold of
20%. The map shows that for most of the surveyed area
there is little uncertainty whether the prevalence of
nodules exceeds the threshold or not: the probability is
in most areas less than 0.1 (highly unlikely that the
prevalence exceeds 20%) or greater than 0.9 (very likely
that the prevalence is greater than 20%). Only for a few
areas is the exceedance probability around 0.5, indicat-
ing that it is uncertain whether the prevalence exceeds
the threshold. Most of these concern transition areas
between high and low endemicity zones.Figure 3 Map of the predictive probability that the local prevalence oTable 3 provides a summary of the classification of the
surveyed area according to the probability that the nod-
ule prevalence exceeds 20%, and compares the results
with those of the classification of high risk areas in the
expert analysis described in the companion paper [36].
Using an exceedance probability of 0.5, it is estimated
that the nodule prevalence exceeds 20% over a total sur-
face of 2.3 million km2 with a population of 59 million
people. However, these estimates are subject to consider-
able statistical uncertainty. Using an exceedance probabil-
ity of 0.9 (highly likely that the nodule prevalence exceeds
20%), the corresponding population is only 36 million.
Using an exceedance probability of 0.1, the populationf nodules exceeds 20%.
Table 3 Comparison of priority areas for treatment identified by the two analytical approaches: expert analysis and
geostatistical analysis













(1000) % of total (1000) % of total (1000) % of total
> 0.9 1,440 35,447 98.0% 25 714 2.0% 1,465 36,161 100.0%
> 0.5 2,193 55,066 93.4% 152 3,877 6.6% 2,345 58,943 100.0%
> 0.1 2, 794 72, 479 80.4% 837 17, 682 19.6% 3,631 90,162 100.0%
Total surveyed area 3,180 83,972 35.4% 5,089 152,986 64.6% 8,270 236,959 100.0%
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ported in the companion article identified high risk areas
with a total surface of 3.2 million km2 and a population
of 84 million (this figure refers to high risk areas within
the surveyed area; the experts also classified an add-
itional 0.11 million km2 of unsurveyed area as ‘assumed’
high risk based on circumstantial evidence, giving a
total of 3.3 million km2 of high risk areas and a popula-
tion of 86 million reported in the companion paper).
Table 3 shows the overlap between the two approaches.
98% of the priority areas for treatment that were identi-
fied with an exceedance probability of 0.9 in the geosta-
tistical analysis were classified as high risk areas by the
experts. The few differences between the two classifica-
tion methods concerned minor differences in the delin-
eation of boundaries of priority areas for treatment,
with the expert analysis drawing boundaries according
to river basins and the model based analysis, which cur-
rently does not include spatial information on rivers,
drawing the boundaries often slightly wider. For the prior-
ity areas identified with the low exceedance probability of
0.1, the agreement with the experts was, unsurprisingly,
poorer; only 80% of this area was classified as high risk by
the experts.
Estimated number infected
The map of the predicted prevalence of nodules in
adults in the 20 APOC countries, together with the re-
cently published relationship between the prevalence of
skin microfilaria and the prevalence of nodules, allowed
the estimation of the total number of people that would
have been infected with O. volvulus in the APOC coun-
tries if there had been no onchocerciasis control. The
results of this analysis are shown in Table 4. It is esti-
mated that overall 35.6 million people (95% confidence
interval 35.1 to 36.1 million) would have been infected by
2011 if there had been no CDTI. Of those, 13.2 million are
from the Democratic Republic of Congo and 8.5 million
from Nigeria.
As reported in the companion article, the prevalence
of nodules was virtually zero in Kenya and Rwanda, sug-
gesting that these two countries are non-endemic foronchocerciasis [36]. However, the necessarily imperfect
calibration relationship between the prevalence of nod-
ules and skin mf prevalence of Coffeng et al [42] shows
that a zero nodule prevalence is compatible with skin mf
prevalence between zero and about four percent. This ex-
plains why, in each of these two presumed non-endemic
countries, our point estimate of the number of infected is
approximately 2% of the population of the surveyed area.Discussion
The geostatistical analysis of the extensive REMO data
for 14,473 surveyed villages has produced a detailed map
of the pre-control geographic distribution of onchocercia-
sis endemicity levels in the 20 APOC countries. This map
has been proven very valuable for onchocerciasis control
and elimination.
Nearly all potentially endemic areas in the 20 APOC
countries have been mapped for onchocerciasis. Of the
total surface area of the 20 countries, 94% has been sur-
veyed for onchocerciasis or classified as unsuitable for
onchocerciasis transmission. By design, no surveys were
done in the unsuitable areas. Although we have no rea-
son to doubt the classification of unsuitability, we were
not able to validate it with survey data. Most of the
remaining 6% of unsurveyed area is either not populated
or has a very low population density of less than 1 per-
son per km2. It also includes a few zones for which it
can reasonably be assumed that onchocerciasis is not en-
demic: the belts between surveyed and unsuitable areas in
central Ethiopia and Kenya where the prevalence of nod-
ules was zero in all neighbouring REMO villages; the
unsurveyed areas in Mozambique south of latitude 18°S
given that only 1 single nodule was detected in 37 villages
surveyed below this latitude; and the coastal low lands of
Tanzania where onchocerciasis vectors have never been
reported [19,25,50]. Only for less than 1% of the total sur-
face area of the 20 APOC countries may surveys still be
needed to estimate the level of onchocerciasis endemicity.
Hence the mapping of onchocerciasis in all potentially en-
demic areas in the APOC countries can be considered
more than 99% complete.
Table 4 Estimated number of people that would have been infected with Onchocerca volvulus in the 20 APOC






in surveyed area (1000)
Number infected with O.volvulus (1000)
Estimate Quantile 0.025 Quantile 0.975
Angola 3.8 1,015 3,812 440 410 475
Burundi 341.0 24 8,252 658 603 717
Cameroon 24.2 430 10,389 2,810 2,674 2,956
CAR 5.2 448 2,312 592 562 624
Chad 21.6 257 5,557 551 516 591
Congo 34.8 271 9,432 512 442 605
DRC 22.1 2,053 45,391 13,155 12,869 13,462
Equatorial Guinea 22.0 23 433 58 55 62
Ethiopia 46.7 446 20,842 2,882 2,677 3,117
Gabon NA 191 722 49 35 66
Kenya NA 57 3,035 68 37 123
Liberia 30.2 96 2,884 554 515 596
Malawi 237.4 77 18,245 817 727 968
Mozambique NA 549 9,889 330 275 398
Nigeria 65.3 858 56,016 8,510 8,292 8,750
Rwanda NA 20 9,550 228 179 283
South Sudan 13.8 535 7,380 1,361 1,269 1,464
Sudan 14.6 346 5,053 58 50 68
Tanzania 19.4 393 7,631 1,061 975 1,152
Uganda 56.4 180 10,135 865 814 925
Total 27.1 8,270 236,959 35,559 35,085 36,116
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was generated in the geostatistical analysis predicts that
before the start of CDTI, onchocerciasis was endemic in
18 of the 20 APOC countries. In Rwanda and Kenya
(where onchocerciasis has been eliminated through vec-
tor control in the 1960s) the prevalence of nodules was
virtually zero and these countries were classified as non-
endemic. In Mozambique, the predicted prevalence of
nodules was around zero throughout the country except
for two small border areas with Tanzania and Malawi. In
these two neighbouring countries there are hyperendemic
onchocerciasis foci close to the border and this resulted in
a predicted nodule prevalence of 15% to 20% just across
the border in Mozambique. In the remaining 17 endemic
countries, the endemicity levels of onchocerciasis varied
significantly. There was a vast belt of hyperendemic on-
chocerciasis covering most of the Democratic Republic
of Congo and extending across west Uganda, South
Sudan, Central African Republic, Chad and Cameroon
into Nigeria. In all of these countries the estimated nodule
prevalence reached levels of over 40%, corresponding to
skin microfilaria prevalence levels of about 60%. There
were also large hyperendemic zones in Ethiopia and
Tanzania with equally high prevalence levels. On theother hand, the estimated prevalence was close or equal
to zero in most of Malawi, Uganda and Sudan, and in
large sections of Burundi, Congo, Gabon, Tanzania, cen-
tral Ethiopia and south-west Central African Republic.
An intermediate pattern with low to medium prevalence
levels was seen in the mainland of Equatorial Guinea
and most of Angola. Overall, the predicted prevalence
of nodules was greater than 20% over a surveyed area
of 2.5 million km2 with an estimated population of 62
million, while the prevalence was between 5% and 20%
over 2.8 million km2 with an estimated population of
77 million.
Beyond the APOC countries, onchocerciasis was known
to be endemic in West Africa where the disease has been
mapped by the OCP [2,51]). To the north of the surveyed
area in the APOC countries are arid zones that are not
suitable for Simulium vectors and which are therefore
onchocerciasis free. For the same reason, Somalia is also
considered onchocerciasis free even though the pres-
ence of S. damnosum s.l. (though not the disease) was
reported from one area in the 1950s [25]. To the south
of APOC, all countries except one are located below the
most southern latitude at which onchocerciasis has ever
been reported. The exception is Zambia. Since Zambia
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have not been done in this country. In the literature
there is only one report from 1983 of an infection with
O. volvulus in a child [52], otherwise onchocerciasis has
never been reported from Zambia. However, in the ab-
sence of systematic survey data, we cannot be certain
that the country is onchocerciasis free, especially for
some border areas.
Compared to the historical information on the geo-
graphic distribution of onchocerciasis in the APOC coun-
tries, the nodule prevalence map is a significant advance.
The WHO Expert Committee on Onchocerciasis Control
of 1995 produced a provisional map of endemic onchocer-
ciasis in Africa on the basis of information available at that
time [1]. Much of the area that the Committee identified
as endemic for onchocerciasis has been confirmed en-
demic in the geostatistical analysis of the REMO data.
However, there were several large areas that the Com-
mittee labeled as non-endemic but that were shown to
have medium to high prevalence levels in the nodule
prevalence map. These include endemic foci in North
Nigeria, South Cameroon, South Sudan, much of Angola,
and several large hyperendemic zones in the Democratic
Republic of Congo where the prevalence of nodules
exceeded 50%-80%. Conversely, several areas labeled as
endemic by the Committee had an estimated nodule
prevalence around zero, e.g. the zone in the south-west
of the Central African Republic and the north of Congo.
A second limitation of the historical data was the lack
of information on onchocerciasis endemicity levels for
most areas. The REMO surveys filled this gap and gener-
ated detailed information on onchocerciasis endemicity
that was critically important for APOC to identify priority
areas for ivermectin treatment, i.e. areas where the preva-
lence of nodules exceeded 20%. Wherever REMO data be-
came available, they were subjected to an expert analysis
that delineated high risk areas where the prevalence of
nodules was greater than 20% and where CDTI was subse-
quently implemented to control the disease as a public
health problem. The results of the expert analysis are de-
scribed in the companion paper. The expert analysis used
a standard methodology to analyse the REMO data within
the context of other relevant geographic information. The
ability to take data from multiple sources into account
was a strength of this methodology but a perceived
weakness was its subjective component: the experts’ in-
terpretation of the information. The geostatistical ana-
lysis involves an objective statistical method that can
take statistical uncertainty into account in the decision
making process on priority areas. Given these fundamental
differences between the two analytical approaches, it was
of interest to compare their results.
Using the geostatistical analysis it was predicted that
the local prevalence of nodules was equal to or greaterthan the threshold of 20% over a total surface area of 2.5
million km2 with a population of 62 million people. This
is less than the high risk area of 3.2 million km2 with a
population of 84 million identified in the expert analysis.
However, in contrast to the expert analysis, the geosta-
tistical estimate has the advantage that it is accompanied
by an estimate of its statistical uncertainty. Taking into
account the probability that the local prevalence exceeds
the 20% threshold, the surface area ranges from 1.5 mil-
lion km2 to 3.6 million km2 for exceedance probabilities
of 0.9 and 0.1 respectively. For exceedance probabilities
of 0.9, nearly all the surface area classified as having a
prevalence of nodules > 20% was also classified as high
risk in the expert analysis. For the low exceedance prob-
ability of 0.1, there was agreement with the expert analysis
for only 80% of the area classified as exceeding the 20%
threshold. The results indicate that the two methods gave
comparable results for areas where the prevalence of
nodules clearly exceeds (i.e. exceedance probability > 0.9)
the threshold of 20%, and where ivermectin treatment is
therefore needed to control onchocerciasis as a public
health problem, but that there is some disagreement for
borderline areas where the prevalence of nodules fluctu-
ates around or below 20%. We conclude that the expert
analysis has correctly identified all areas for which there is
strong evidence that ivermectin treatment is needed to
control onchocerciasis as a public health problem. It also
includes many borderline areas for which the evidence of
high risk is less strong, but this has been considered justi-
fied for ethical reasons so as not to exclude isolated high-
risk communities from treatment [36].
The geostatistical analysis has also been used to esti-
mate the total number of people that would have been
infected with O. volvulus in the 20 APOC countries if
there had been no CDTI. Based on the nodule preva-
lence map and the recently published quantification of
the relationship between the prevalence of skin microfil-
aria and the prevalence of onchocercal nodules [42], we
estimate that some 35.6 million people (95% confidence
interval 35.1 to 36.1 million) would have been infected
by the year 2011 if there had been no CDTI. This esti-
mate is significantly higher than the most commonly
quoted estimate from the WHO Expert Committee on
Onchocerciasis Control which estimated that in 1995 a
total of 17.7 million people were infected globally, of
which 15.0 million lived in APOC countries [1]. Using
an annual rural population growth rate of 2.2% for the
APOC countries [53], our estimate of 36 million infected
for 2011 corresponds to 25 million infected in 1995, i.e.
10 million more than the previous WHO estimate for
the APOC countries. This difference is not surprising
given that REMO identified many new endemic areas and
generated prevalence estimates for all areas. However,
compared to other, more recent estimates our figure
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32 million people infected in the APOC countries in
1995, and Remme et al. [55] estimated 37 million
people infected globally in 1995 and also about 32 mil-
lion for the APOC countries. These estimates are also
largely based on APOC’s REMO data. The difference
with our estimate is mainly due to two methodological
factors. One concerns the formula used to quantify the
relationship between the prevalence of microfilaria and
the prevalence of nodules. We used a formula from a re-
cently published analysis of data from West, Central
and East Africa [42] which predicts a lower prevalence
of microfilariae for a given prevalence of nodules than
the formulas used previously. The second factor con-
cerns the way the REMO sampling design has been
taken into account. The previous estimates assume that
sample villages were selected randomly from a given
area. However, in the REMO sampling method villages
are selected spatially at regular distances along rivers
with potential breeding sites and at lower sampling
density between rivers. Because of this design, the selec-
tion of villages to be surveyed is biased towards villages
with a high endemicity level close to breeding sites and
this bias may have resulted in an overestimate of the
number infected in previous studies. The current geos-
tatistical analysis partially corrects for this bias by tak-
ing into account the spatial distribution of the survey
data. Specifically, in estimating the total number in-
fected, one effect of the spatial correlation is that the
observed prevalence from an isolated surveyed village
acts as a proxy for the results that would have been ob-
tained had surrounding villages also been surveyed, and
therefore has greater influence than any one of a number
of surveyed villages at mutually close locations. This re-
sults in a discrepancy between the crude average preva-
lence and the spatially averaged modelled prevalence.
A possible improvement of the geostatistical analysis
of the REMO data would be to include relevant geo-
graphical covariates in the geostatistical model [56], such
as the distance to the nearest river with breeding sites,
local Simulium species and vegetation. This will not be
easy as the distribution of the different Simulium species
is not well known for most areas while the identification
of rivers with potential for Simulium breeding is a chal-
lenge, especially in forest areas. However, recent progress
in the development of a remote sensing model to identify
S. damnosum s.l. breeding sites in Africa appears promis-
ing [57]. If this approach can be made to work also in for-
est areas, and if the cost of its large scale application can
be reduced, it should be possible to improve the nodule
prevalence map by including in the model the distance to
the nearest potential S. damnosum breeding site as identi-
fied by remote sensing data. Another possible improve-
ment of the model concerns predictions in areas wherethe prevalence is zero. A common feature of prevalence
survey data, here and elsewhere, is an excess of zeros by
comparison with the best-fitting binomial distribution.
In a spatial setting, this zero-inflation can be artificial;
for example, it could be the result of over-sampling in
low-prevalence areas. In principle, geographical covari-
ate information could again be used to model genuine
zero-inflation [58]. In our analysis, we dealt with this by
adding dummy zero prevalence data at points within
areas known to be disease-free (eg deserts and large
water-bodies), thereby ensuring that our estimated preva-
lence approaches zero at the boundaries of each of these
areas. We intend to develop an extended model which
treats zero-inflation as a second spatial stochastic process
for applications where areas of true zero prevalence are
not known beforehand and prediction of such areas is im-
portant. One such application is the use of the REMO data
for helping to revise ivermectin treatment boundaries for
the purpose of onchocerciasis elimination. Finally, bias
would arise if implementers deliberately sampled com-
munities whose prevalence was atypical of their general
localities, a phenomenon called preferential sampling.
Correcting for the effects of preferential sampling is dif-
ficult unless it can be explained by measured covariates
such as distance to the nearest river in the case of on-
chocerciasis [56].
The original objective of REMO was to identify target
areas for ivermectin treatment with the aim of controlling
onchocerciasis as a public health problem. In recent years
evidence has emerged that in the long term onchocerciasis
infection and transmission can even be eliminated with
CDTI [59-61]. Based on this new evidence, APOC has
adopted an additional objective to eliminate onchocer-
ciasis where feasible [62]. Because of this paradigm shift,
the target areas for CDTI are currently being revised to in-
clude all areas with local onchocerciasis transmission. The
nodule prevalence map provides the starting point for de-
termining the new treatment boundaries. Furthermore,
the number of years of ivermectin treatment that is re-
quired to achieve elimination depends strongly on the
local endemicity level [63]. Information on pre-control en-
demicity levels is therefore essential for the correct inter-
pretation of the results of epidemiological evaluations of
the impact of CDTI on onchocerciasis infection levels,
and for the prediction of the remaining number of years
of CDTI needed in a given area [40]. This information is
now also available for all CDTI areas from the nodule
prevalence map.
Conclusions
APOC is close to achieving the objective of controlling
onchocerciasis as a public health problem throughout the
APOC countries, and the REMO data and nodule preva-
lence maps have played an essential role in targeting
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Following the shift from onchocerciasis control to on-
chocerciasis elimination, the nodule prevalence map
will continue to play an important role and help with
adjusting treatment boundaries, interpreting epidemio-
logical evaluation data on progress towards elimination
and predicting when elimination will be achieved in dif-
ferent areas. REMO was a major undertaking but it has
been worthwhile and the results have been very valuable
for onchocerciasis control and elimination in Africa.
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